AstraZeneca Oncology

 

Immunotherapies
06:27

AstraZeneca Oncology

Importance of Proactive AE Management and Patient Education for Concurrent CRT in Unresectable Stage III NSCLC

FEATURING Roy Decker, Jhanelle Gray, Joe Chang, Victoria Sherry, Victoria Villaflor, Mark Socinski, Kristin Higgins
  • 1,123 views
  • November 15, 2019
  • 2
06:01

AstraZeneca Oncology

Advances in Radiation Technology May Improve Concurrent CRT in Unresectable Stage III NSCLC

FEATURING Roy Decker, Mark Socinski, Joe Chang, Kristin Higgins
  • 595 views
  • November 15, 2019
  • 2
04:40

AstraZeneca Oncology

Even Patients With Locally Advanced Stage III NSCLC May Be Treated With Curative Intent

FEATURING Roy Decker, Jhanelle Gray, Joe Chang, Mark Socinski, Kristin Higgins
  • 932 views
  • November 15, 2019
  • 2
03:43

AstraZeneca Oncology

Effective Communication between Radiation and Medical Oncologist May Improve Concurrent CRT in Unresectable Stage III NSCLC

FEATURING Roy Decker, Mark Socinski, Jhanelle Gray, Mary Grizzard
  • 914 views
  • November 15, 2019
  • 3